Christian Maasch

This inventor holds 26 USPTO granted patents and 15 published patent applications, plus 5 CIPO patents and 11 EPO patents, primarily in Nucleic Acid Therapeutics. Top assignees: Noxxon Pharma Ag, Aptarion Biotech Ag. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christian Maasch. Retrieved from https://idiyas.com/inventor/christian-maasch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 15)

% Patents Active = 65.4

CIPO Patents = 5 (Patent Applications = 6)

EPO Patents = 11 (Patent Applications = 14)

Average Co-Inventor Count = 6.1

ph-index = 6

Forward Citations = 74(Granted Patents)

Company Filing History:

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

CXCL8

C5a

MCP-1

SDF-1

Nucleic Acid

Binding Affinity

Cancer Treatment

Spiegelmers

Ghrelin

CGRP

Intracellular Target

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12359206 - CXCL8 binding nucleic acids (2025-07-15),

2. 12188021 - C5a binding nucleic acids (2025-01-07),

3. 11492625 - C5a binding nucleic acids (2022-11-08),

4. 10590424 - C5a binding nucleic acids (2020-03-17),

5. 10273480 - MCP-1 binding nucleic acids (2019-04-30),

6. 10093934 - SDF-1 binding nucleic acids and the use thereof in cancer treatment (2018-10-09),

7. 9988636 - SDF-1 binding nucleic acids and the use thereof (2018-06-05),

8. 9976145 - Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same (2018-05-22),

9. 9822369 - SDF-1 binding nucleic acids (2017-11-21),

10. 9670491 - MCP-1 binding nucleic acids (2017-06-06),

11. 9518265 - C5a binding nucleic acids (2016-12-13),

12. 9387221 - SDF-1 binding nucleic acids and the use thereof in cancer treatment (2016-07-12),

13. 9163243 - Nucleic acids specifically binding CGRP (2015-10-20),

14. 9074214 - Use of spiegelmers (2015-07-07),

15. 9035038 - SDF-1 binding nucleic acids (2015-05-19),

Title: **Christian Maasch: Innovator in Nucleic Acid Technology**

Introduction

Christian Maasch is a distinguished inventor based in Berlin, Germany, known for his significant contributions to the field of nucleic acids. With an impressive portfolio of 25 patents, Maasch has made remarkable advancements in the biotechnology sector, particularly in binding mechanisms related to human proteins.

Latest Patents

Among his latest inventions is the innovative patent for C5a binding nucleic acids. The invention focuses on a nucleic acid molecule adept at binding to human C5a. This groundbreaking molecule includes a unique nucleotide sequence: 5' AUGnGGUGKUnnRGGGHUGUKGGGnGnCGACGCA 3′ [SEQ ID NO: 61]. The complexity of the molecule allows it to incorporate various ribonucleotides and 2′-deoxyribonucleotides, indicating a sophisticated approach towards molecular binding.

Career Highlights

Throughout his career, Christian Maasch has demonstrated a strong commitment to scientific research and innovation. He has been an integral part of reputable organizations such as Noxxon Pharma and Aptarion Biotech, where he has utilized his expertise to drive advancements in biotechnology.

Collaborations

Maasch has collaborated with notable colleagues in the scientific community, including Sven Klussmann and Klaus Buchner. These partnerships have further enhanced his research capabilities and contributed to his prolific output in patent applications.

Conclusion

Christian Maasch stands out as a leading figure in the realm of nucleic acid technology. His numerous patents and impactful collaborations illustrate his dedication to innovation in biotechnology, marking him as an influential inventor in the field.

Profile summary based on public USPTO records.